You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,563,949


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,563,949
Title:Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
Abstract: The present invention is directed to nucleic acid molecules and nucleic acid constructs, and other agents associated with fatty acid synthesis, particularly the ratios of saturated and unsaturated fats. Moreover, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of saturated and unsaturated fats. In particular, the present invention is directed to plants incorporating such agents where the plants exhibit altered ratios of monounsaturated to polyunsaturated fatty acids.
Inventor(s): Fillatti; JoAnne J. (Davis, CA)
Assignee: Monsanto Technology LLC (St. Louis, MO)
Application Number:11/369,993
Patent Claims:1. A transgenic soybean plant comprising a recombinant nucleic acid molecule with a nucleic acid sequence at least 95% identical to the FAD2-1A intron (SEQ ID NO: 1), wherein the level of a transcript encoded by said FAD2-1A is significantly reduced relative to a soybean plant with a similar genetic background without said recombinant nucleic acid molecule while there are no significant differences in the level of a transcript encoded by FAD2-2B.

2. The transgenic soybean plant of claim 1, wherein said level of a transcript encoded by FAD2-1A is significantly reduced by at least 50%.

3. The transgenic soybean plant of claim 1, wherein said level of a transcript encoded by FAD2-1A is significantly reduced by at least 75%.

4. The transgenic soybean plant of claim 1, wherein FAD2-2B is at least 95% identical over the entire length of the nucleic acid molecule with the nucleotide sequence of SEQ ID NO: 4.

5. The trangenic soybean plant of claim 1, wherein said nucleic acid sequence is at least 98% identical to the FAD2-1A intron.

6. The trangenic soybean plant of claim 1, wherein said nucleic acid sequence is 100% identical to the FAD2-1A intron.

7. The trangenic soybean plant of claim 1, wherein said nucleic acid sequence at least 95% identical to the FAD2-1A intron is operably linked to a seed-specific promoter.

8. A transgenic soybean plant comprising a recombinant nucleic acid molecule with a nucleic acid sequence at least 95% identical to about 200 to about 400 contiguous nucleotides of the FAD2-1A intron (SEQ ID NO: 1), wherein the level of a transcript encoded by FAD2-1A is significantly reduced relative to a soybean plant with a similar genetic background without said recombinant nucleic acid molecule while there are no significant differences in the level of a transcript encoded by FAD2-2B.

Details for Patent 7,563,949

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2019-08-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2019-08-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2019-08-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.